Pitavastatin: addressing challenges: JAPAN-ACS and CIRCLE studies
EAS Academy, Hidenori Arai, 21241
Pitavastatin for the management of dyslipidaemia and atherosclerosis
EAS Academy, José-Ramon Gonzalez -Juanatey, 21240
Managing dyslipidaemia complicated with diabetes or high cardiovascular risk: how well are we doing?
EAS Academy, John Betteridge, 21239
CAN WE ENCOURAGE OUR HYPERCHOLESTEROLEMIC PATIENTS TO TAKE PLANT STEROL ENRICHED FOODS?
EAS Academy, Eric Bruckert, 21237
ARE LIPOPROTEIN REMNANTS A REASONABLE TARGET FOR THERAPY?
EAS Academy, Henry Ginsberg, 20869
GENETICS OF ATHEROGENIC DYSLIPIDEMIAS
EAS Academy, Robert Hegele, 20868
NOVEL ANTI-ATHEROGENIC MECHANISMS OF HDL AND ABC TRANSPORTERS
EAS Academy, Alan Tall, 20867
THE MACROPHAGE LIPOPROTEIN INTERACTIONS – FOR GOOD OR FOR BAD
EAS Academy, Miranda van Eck, 20866
New treatment options in patients with severe heterozygous FH: applying antisense technology
EAS Academy, Christie M. Ballantyne, 21236
Metabolic regulation of apoB-containing lipoproteins in severe FH
EAS Academy, Gerald Watts, 21235
Risk factors in severe heterozygous FH
EAS Academy, Eric Bruckert, 21234
Improving patient management – how implementation of the latest guidelines will help
EAS Academy, Lale Tokgözoglu, 21231
Treatment challenges in patients with familial hypercholesterolaemia
EAS Academy, Marcello Arca, 21230
Further reducing cardiovascular risk – what to target?
EAS Academy, Julian Halcox, 21229
UNDERSTANDING THE VULNERABLE PLAQUE – BASIS FOR TREATMENT OPTIONS
EAS Academy, Gerard Pasterkamp, 20863
IMMUNITY IN ATHEROSCLEROSIS
EAS Academy, Goran Hansson, 20862
ENDOTHELIAL FUNCTION AND DYSFUNCTION: THE KEYS TO CORONARY AND PERIPHERAL CIRCULATION
EAS Academy, Ulf Landmesser, 20861
BUILDING A VESSEL WALL: FROM DEVELOPMENTAL BIOLOGY TO PHYSIOLOGICAL AND PATHOLOGICAL REMODELING IN ADULT LIFE
EAS Academy, Mark Majesky, 20860
Module 1: A brief history of cholesterol lowering
EAS Academy, Terje R Pedersen, 99030
Intoduction to the Anitschkow lecture
EAS Academy, John M. Chapman, 20857
A BRIEF HISTORY OF CHOLESTEROL LOWERING
EAS Academy, Terje R Pedersen, 20858
Module 10: Pharmacological treatment of hypercholesterolemia
EAS Academy, EAS, 65171
Carotid Intima-Media Thickness Measurement
EAS Academy, Alberico Luigi Catapano, 31176
Assessment of the Brachial Artery Response- Flow-Mediated Dilation
EAS Academy, Alberico Luigi Catapano, 31177
Comprehensive management of dyslipidemic patients at risk: Should we prescribe antiaggregants?
EAS Academy, Jean-Philippe Collet, 18304
New advances in the role of Lp(a) in atherosclerosis; Therapeutic implications
EAS Academy, Børge Nordestgaard, 18303
Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Alain Carrié, 18302
Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Eric Bruckert, 18301
New Therapeutic Approaches in Lipidology
EAS Academy, John M. Chapman, 18300
Imaging of arteries: does it help to improve risk evaluation?
EAS Academy, Lale Tokgözoglu, 18299
Update on new EAS/ESC Joint European Guidelines for the Prevention and Treatment of Dyslipidemia
EAS Academy, Olov Wiklund, 18298
CV Risk evaluation through Algorithms
EAS Academy, Eric Bruckert, 18297
Update on HDL biology: structure , metabolism and function in health and disease
EAS Academy, John M. Chapman, 18296
THE NEW EAS/ESC GUIDELINES TO TREAT DYSLIPIDEMIAS
EAS Academy, Alberico Luigi Catapano, 8236
Module 8: What is a healthy diet, as defined by the criteria of evidence-based medicine?
EAS Academy, Gabriele Riccardi, 99038
WHAT IS A HEALTHY DIET, AS DEFINED BY THE CRITERIA OF EVIDENCE-BASED MEDICINE?
EAS Academy, Gabriele Riccardi, 8235
IMMUNE MODULATION/VACCINATION TO TREAT AND PREVENT ATHEROSCLEROSIS
EAS Academy, Jan Nilsson, 8234
THE ROLE OF INFLAMMATORY BIOMARKERS IN DAILY DECISION MAKING
EAS Academy, Børge Nordestgaard, 8233
NEW IMAGING POSSIBILITIES IN ATHEROSCLEROSIS
EAS Academy, James Rudd, 8231
THE CELLULAR BIOLOGY OF PLAQUE NECROSIS
EAS Academy, Ira Tabas, 8230
PATHOLOGY OF THE VULNERABLE PLAQUE: WHAT DOES IT LOOK LIKE?
EAS Academy, Erling Falk, 8229
DIVERSITY OF HDL PARTICLES - A CHALLENGE FOR TREATMENT
EAS Academy, John M. Chapman, 8225
POST-PRANDIAL LIPID METABOLISM
EAS Academy, Stephen Young, 8227
NEW INSIGHTS INTO THE ETIOLOGY AND PATHOPHYSIOLOGY OF HEREDITARY DYSLIPIDEMIAS
EAS Academy, Helen Hobbs, 8226
THE ANITSCHKOW LECTURE: CETP INHIBITION AS A STRATEGY TO REDUCE CARDIOVASCULAR RISK
EAS Academy, Philip Barter, 8224
CLOSE
EAS Academy, Andrew A. Tonkin, 8249
HOT TOPICS IN TARGETED INTERVENTION OF CVD RISK
EAS Academy, Session Speakers, 8989
NEW OPPORTUNITIES FOR CARDIOVASCULAR DISEASE PREVENTION
EAS Academy, Stephen Nicholls, 8248
VASCULAR FUNCTION - THERAPEUTIC TARGET OR CARDIOVASCULAR RISK MARKER
EAS Academy, John Deanfield, 8253
HOT TOPICS IN THE IMPLEMENTATION OF GUIDELINES IN CLINICAL PRACTICE
EAS Academy, Session Speakers, 8988
IMPLEMENTING EFFECTIVE CVD RISK MANAGEMENT IN CLINICAL PRACTICE
EAS Academy, David A. Wood, 8247
TEST
EAS Academy, Session Speakers, 9544
HOT TOPICS RELATING TO THE CHALLENGES FACED IN EFFECTIVE CARDIOVASCULAR RISK MANAGEMENT
EAS Academy, Session Speakers, 8987
CHALLENGES TO EFFECTIVE CARDIOVASCULAR RISK MANAGEMENT
EAS Academy, Alberto Zambon, 8246
HDL FUNCTION AND REVERSE CHOLESTEROL TRANSPORT IN HUMANS: CAN THEY BE PROMOTED BY THERAPEUTIC INTERVENTION?
EAS Academy, Marina M. Cuchel, 8251
Module 4: The role of inflammatory biomarkers in daily decision making
EAS Academy, Børge Nordestgaard, 99033

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings